GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Anhui Wanbang Pharmaceutical Technology Co Ltd (SZSE:301520) » Definitions » Capex-to-Operating-Income

Anhui Wanbang Pharmaceutical Technology Co (SZSE:301520) Capex-to-Operating-Income : 2.21 (As of Mar. 2025)


View and export this data going back to 2023. Start your Free Trial

What is Anhui Wanbang Pharmaceutical Technology Co Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Anhui Wanbang Pharmaceutical Technology Co's Capital Expenditure for the three months ended in Mar. 2025 was ¥-9.16 Mil. Its Operating Income for the three months ended in Mar. 2025 was ¥4.15 Mil.

Hence, Anhui Wanbang Pharmaceutical Technology Co's Capex-to-Operating-Income for the three months ended in Mar. 2025 was 2.21.


Anhui Wanbang Pharmaceutical Technology Co Capex-to-Operating-Income Historical Data

The historical data trend for Anhui Wanbang Pharmaceutical Technology Co's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anhui Wanbang Pharmaceutical Technology Co Capex-to-Operating-Income Chart

Anhui Wanbang Pharmaceutical Technology Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Capex-to-Operating-Income
Get a 7-Day Free Trial 0.12 0.18 0.49 0.77 0.68

Anhui Wanbang Pharmaceutical Technology Co Quarterly Data
Dec18 Dec19 Dec20 Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.64 0.60 0.67 2.74 2.21

Competitive Comparison of Anhui Wanbang Pharmaceutical Technology Co's Capex-to-Operating-Income

For the Drug Manufacturers - Specialty & Generic subindustry, Anhui Wanbang Pharmaceutical Technology Co's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anhui Wanbang Pharmaceutical Technology Co's Capex-to-Operating-Income Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Anhui Wanbang Pharmaceutical Technology Co's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Anhui Wanbang Pharmaceutical Technology Co's Capex-to-Operating-Income falls into.


;
;

Anhui Wanbang Pharmaceutical Technology Co Capex-to-Operating-Income Calculation

Anhui Wanbang Pharmaceutical Technology Co's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2024 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-41.823) / 61.505
=0.68

Anhui Wanbang Pharmaceutical Technology Co's Capex-to-Operating-Income for the quarter that ended in Mar. 2025 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-9.16) / 4.148
=2.21

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Anhui Wanbang Pharmaceutical Technology Co  (SZSE:301520) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


Anhui Wanbang Pharmaceutical Technology Co Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Anhui Wanbang Pharmaceutical Technology Co's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Anhui Wanbang Pharmaceutical Technology Co Business Description

Traded in Other Exchanges
N/A
Address
southwest corner of the intersection of Mingzhu Avenue and Huolongdi Road, Building 1, Anhui Wanbang Pharmaceutical, High-tech Zone, Anhui, Hefei, CHN, 230000
Anhui Wanbang Pharmaceutical Technology Co Ltd is a one-stop CRO service platform that engages in the entire process from pharmaceutical development to clinical research of innovative drugs, improved new drugs and generic drugs. It aims to provide drug research and development and clinical trials for drug launch, including pharmaceutical research, clinical services, biological sample analysis and testing, SMO services and data statistics and analysis.

Anhui Wanbang Pharmaceutical Technology Co Headlines

No Headlines